PulseTrendingJournal ClubResearchersJournalsExplore
Instagram
HomeTrendingJournal ClubExplore
Synapse
⌘+K
Synapse
June 26, 2026Blood Cancer Discovery

Abstract A028: Targeting eIF4A1 reveals crosstalk between BCR signaling and translation in aggressive B-cell lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

FKForum KayasthaBKBandish KapadiaARAnirban Roychowdhury

Discussion

Loading...

Member takes

Overview

Randomized trial assesses eIF4A1 inhibition effects on tumor growth in aggressive B-cell lymphoma, suggesting new treatment paths.

Key Points

  • Investigate how eIF4A1 affects protein synthesis in aggressive B-cell lymphomas and its therapeutic potential.
  • Analyzed lymphoma datasets and tumor samples for eIF4A1 expression levels.
  • Developed small-molecule inhibitors of eIF4A1 and tested their effects on lymphoma cell proliferation.
  • Used orthotopic lymphoma models to evaluate the impact of inhibitors on tumor growth.
  • Elevated eIF4A1 expression correlates with poor clinical outcomes in diffuse large B-cell lymphoma.
  • Inhibition of eIF4A1 reduces oncogenic protein expression (MYC, BCL2, CCND1) and lymphoma cell proliferation.
  • RBF197 significantly inhibits tumor growth in orthotopic models while demonstrating favorable pharmacokinetics.

Cite This Study

Kayastha et al. (2026) studied this question.

synapsesocial.com/papers/6a3e18d0030ad1a9b3091c73https://doi.org/10.1158/2643-3249.lymphoma26-a028
View Full Paper
Ask AI
Bookmark
Share